Pattern’s P2PAR immunotherapeutic has proven efficacy in humans against a range of infectious diseases (viral infections etc.) and oncology indications. P2PAR activates the innate immune system, the first line of defense against pathogens, and also mobilizes the adaptive immune system through in situ vaccination. Pattern is focused on testing P2PAR’s clinical efficacy in COVID-19, in both therapeutic and prophylactic settings.  

Pattern Pharma Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total